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ombitasvir/dasabuvir) +/- ribavirin compared with Harvoni® (sofosbuvir/ledipas-
vir) in the United States. METHODS: A cost-effectiveness Markov model, based 
on previous HCV models, had 13 health states: 8 disease progression states (F0-
F4, decompensated cirrhosis, hepatocellular carcinoma, and liver transplant), 3 
sustained virologic response states, and 2 mortality states (liver-related and non-
liver-related death). Transition rates were obtained from previous models. Adverse 
events, treatment-related disutility, and efficacy rates were based on phase 3 clini-
cal trials. Baseline patient characteristics were derived from AbbVie 3D phase 3 
clinical trials. Treatment durations were 24 weeks for GT1a experienced cirrhotic 
patients with AbbVie 3D and 8 weeks for 26% of GT1 treatment naïve patients with 
Harvoni. Direct medical costs were based on a systematic literature review and drug 
costs were based on December 2014 Red Book. The model was run over a lifetime 
horizon, discounting at 3% annually. Outcomes were measured in quality-adjusted 
life-years (QALYs). Probabilistic simulation analysis (PSA) was conducted by varying 
all parameters simultaneously. RESULTS: AbbVie 3D resulted in discounted lifetime 
costs per patient of $99,753 and 16.20 QALYs. Harvoni resulted in lifetime costs of 
$108,430 and 16.18 QALYs. With lower costs (-$8,677) and higher QALYs (0.02), AbbVie 
3D dominated Harvoni. AbbVie 3D was superior in 98.4% of PSA simulations when 
QALYs were valued at $100,000 each. CONCLUSIONS: With higher QALYs and lower 
costs, AbbVie 3D dominated Harvoni in GT1-HCV-infected patients.
PGI22
AssessInG the cost-effectIveness of A UnIversAl rotAvIrUs 
vAccInAtIon ProGrAm for the PhIlIPPInes UsInG A dynAmIc 
trAnsmIssIon model
Lam H.Y.1, Wu D.B.2, Rivera A.S.1, Alejandria M.M.1, Velasco G.N.3, Sison O.T.1, Ladia M.A.1, 
Mantaring J.b.1, Santillan M.4
1University of the Philippines Manila, Manila, Philippines, 2Monash University Malaysia, Subang 
Jaya, Malaysia, 3Department of Health Philippines, Manila, Philippines, 4Philippine Health 
Insurance Corporation, Pasig City, Philippines
OBJECTIVES: Evaluate the cost-effectiveness of universal rotavirus vaccination of 
children below age of five years old in the Philippine setting METHODS: We developed 
an age-stratified dynamic transmission model which compared four settings (baseline 
of no vaccine with 34% exclusive breastfeeding rate (EBR), two-dose monovalent vac-
cine (RV1), three-dose pentavalent vaccine (RV5), and no vaccine with 80% EBR) in the 
Philippine population over a 5-year time horizon. Model parameters such as cost and 
vital statistics were Philippine specific and other parameters such as vaccine efficacy 
and utility were extrapolated from literature. Univariate one-way and multivariate 
probabilities sensitivity analyses were conducted. RESULTS: Compared to baseline, 
the model showed that vaccination could lead to significant reduction in rotaviral 
morbidity and mortality in the 0 to < 5 age group as well as inducing herd immunity in 
the older groups. The incremental cost-effectiveness ratios (ICER) of vaccination ver-
sus baseline from a societal perspective were US$ 13,184/DALY for RV1 and US$ 11,836/
DALY for RV5; these are higher than the the current government cost-effectiveness 
threshold equal to the Philippine GNI per capita of US$ 3,134. Comparing 80% EBR 
to baseline, ICER is US$ 256,417/DALY. ICERs were sensitive to changes in case fatal-
ity, proportion of diarrhea cases due to rotavirus, and vaccine efficacy. The vaccine 
was cost-effective in less than 10% of 5000 Monte Carlo simulations. We estimated 
cost-effective prices of US$ 2.85/dose RV1 and US$ 1.96/dose RV5 which were lower 
than the current price of US$ 9.85/dose RV1 and US$ 6.43/dose RV5. CONCLUSIONS: 
Despite herd immunity benefits, universal vaccination using either RV1 or RV5 is 
unlikely to be cost-effective, at current tendered prices, for the Philippine setting, 
despite the herd immunity benefits. It might be due to comparatively low case-fatality 
rates. Current prices need to be decreased around 70% to achieve cost-effectiveness.
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OBJECTIVES: To assess the cost-effectiveness of daclatasvir plus asunaprevir 
(DCV/ASV) versus peginterferon plus ribavirin (PR) and first generation protease 
inhibitors (PIs) for the treatment of patients with hepatitis C genotype 1b, from the 
perspective of the Chilean public healthcare system. METHODS: A Markov cohort 
model (MONARCH) was built to estimate the expected costs in Chilean pesos (CL$) 
and benefits in quality adjusted life years (QALYs) from aggregated data. Efficacy 
was obtained from a mixed-treatment comparison study and costs were estimated 
from local sources. Utilities were estimated from the literature. A time horizon 
of 46 years and a 3% discount rate was considered for costs and outcomes. Three 
groups of patients were examined: untreated (naïve), partial responders and non-
responders. The ICER in naive patients is presented for a range of DCV/ASV prices. 
Deterministic and probabilistic sensitivity analyses were performed. RESULTS: PIs 
were extendedly dominated by DCV/ASV. In naïve patients the ICER of DCV/ASV 
compared to PR was CL$ 15,696,479/QALY (US$26,160/QALY) at a treatment price 
of CL$48,000,000 (US$79,200); CL$10,751,318/QALY (US$17,918/QALY) at a price 
of CL$36,000,000 (US$60,000); CL$5,950,954/QALY (US$9,918/QALY) at a price of 
CL$24,000,000 (US$40,000); and CL$1,278,270/QALY (US$2,130/QALY) at a price of 
CL$12,000,000 (US$20,000). Whilst the probability of cost-effectiveness at a price 
of CL$36,000,000 was 59%, there is a 45% probability that DCV/ASV dominates PR 
if the price was CL$12,000,000. The ICER for partial responders was CL$6,082,698/
QALY (US$10,137/QALY) and for non-responders CL$6,603,023/QALY (US$11,005/
QALY) at a DCV/ASV price of CL$36,000,000. The ICER was more sensitive to the 
discount rate, efficacy of DCV/ASV and the utility of the sustained viral response 
state in cirrhotic patients CONCLUSIONS: DCV/ASV can be considered cost-
effective at some particular price range. These results provide decision makers 
useful information about the value of incorporating these drugs into the public 
Chilean healthcare system.
compared to infliximab was $3.5 million/QALY. Certolizumab pegol and vedolizumab 
were eliminated by extended dominance. In comparison between infliximab and 
active control, the model was robust to all variables in one-way sensitivity analysis. 
Results comparing adalimumab and infliximab were sensitive to utility values. In 
the PSA, infliximab was 99.6% cost-effective compared to active control; however, 
adalimumab was only 2.6% cost-effective. CONCLUSIONS: Infliximab is cost-effective 
relative to active control, whereas, adalimumab is not when compared to infliximab. 
Other studies have reported varying results which highlights the importance for 
further work in this area.
PGI19
heAlthcAre costs of A consecUtIve cohort of PAtIents wIth 
UlcerAtIve colItIs And crohn’s dIseAse treAted At A tertIAry 
medIcAl center In IsrAel
Odes S.1, Vardi H.1, Friger M.1, Schwartz D.2, Sarid O.1, Slonim-Nevo V.1, Greenberg D.3
1Ben-Gurion University of the Negev, Beer Sheva, Israel, 2Soroka Medical Center, Beer Sheva, 
Israel, 3Ben-Gurion University of the Negev, Beer-Sheva, Israel
OBJECTIVES: Up-to-date estimation of healthcare costs in Ulcerative Colitis (UC) and 
Crohn’s Disease (CD) patients is crucial to inform budgeting and resource allocation 
decisions. Recent introduction of biologic therapies rendered previous cost studies 
with standard therapy obsolete. We sought to determine healthcare costs in a con-
secutive sample of real-world UC and CD patients managed in a specialized facility 
in a tertiary referral center in Israel. METHODS: Data-bases of patients enrolled in an 
ongoing socio-economic study were mined to determine healthcare resource utiliza-
tion during the years 2012 and 2013. This included direct charges for in-patients and 
out-patients, hospitalizations, investigations and medical and surgical treatments. 
Prices were obtained from the Ministry of Health Tariff (12/2014) and expressed as US 
$. Data express costs related to UC and CD patients, excluding any treatments for co-
morbidities. RESULTS: This adult cohort had a mean age of 45.1 ± 17.2 years, with M:F 
ratio 1.04. The mean [median] healthcare cost/patient was: UC, 2012 (n= 273): $1,710 
[$847], 2013 (n= 280): $1,983 [$916]; CD, 2012 (n= 263): $4,231 [$1,450], 2013 (n= 280): 
$4,568 [$1,169]. Between-year differences in costs were not statistically significant. 
Over the two-year period, the major cost drivers in UC were procedures (37.3% of 
costs), consultations (20.4%), biologic medication (17.8%), standard medication (13.5%) 
and hospitalization (9.4%). In CD, the cost drivers were biologic medication (47.4%), 
surgery (13.8%), procedures (12.1%), consultations (11.21%), hospitalization (10.7%) and 
standard medication (4.8%). Mean biologic medication cost/patient in UC increased 
from $293 in 2012 to $352 in 2013; and for CD from $1882 to $2289 respectively. This 
paralleled an increase in the number of patients receiving biologic medication from 
65 in 2012 to 76 in 2013; of these, 81% had CD. CONCLUSIONS: CD patients engender 
much higher healthcare costs that those with UC. Expensive biologic medication 
now becomes the major cost driver in CD, but not UC, patients in the current era.
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OBJECTIVES: Although the high cost burden of chronic hepatitis C (CHC) has been 
described in the literature, there is a lack of data on the assessment of characteristics 
associated with high healthcare utilizers. The purpose of this study was to identify 
demographics and clinical characteristics associated with high healthcare utilizers 
and liver disease progression among CHC patients. METHODS: Health insurance 
claims from 60 self-insured US companies were analyzed (01/2001-03/2013). Adult 
patients with ≥ 2 CHC claims (ICD-9-CM: 070.44 or 070.54), ≥ 6 months of continu-
ous insurance coverage before the first CHC diagnosis and ≥ 36 months after were 
included. Patients with HIV were excluded. Demographics and baseline comorbidi-
ties including CHC- and non-CHC-related conditions were described. Generalized 
estimating equations with logit link for binary outcomes were used to identify the 
most predictive demographics and clinical characteristics of being in the 20% of 
patients with the highest healthcare resource utilization (HRU). Predictive factors of 
liver disease progression were also identified. RESULTS: The mean age of the study 
population (N= 4,898) was 52.4 years and 39.4% were female. Compensated cirrhosis, 
ESLD and both CHC- and non CHC-related comorbidities were strong predictors of 
high healthcare costs, with odds ratios (ORs; 95%CI) for ESLD, ≥ 2 CHC-related, and ≥ 2 
non CHC-related comorbidities of 3.31 (2.80-3.92), 2.78 (2.47-3.12), and 2.18 (1.75-2.71), 
respectively. CHC- and non CHC-related comorbidities were also strong predictors of 
liver disease progression with ORs (95%CI) for ≥ 2 CHC-related and ≥ 2 non CHC-related 
comorbidities of 2.18 (1.83-2.60) and 1.50 (1.14-1.97), respectively. CONCLUSIONS: This 
real-world study suggests that CHC patients with the highest HRU and costs had a 
high level of comorbidity at baseline and that non-CHC conditions are strong predic-
tors of high healthcare costs. Liver disease severity alone does not fully predict high 
consumption of HRU, although when present it is a predictor of high HRU.
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OBJECTIVES: Interferon (INF)-free therapies for the treatment of hepatitis C virus 
(HCV) offer better viral clearance rates and safety profiles than older therapies 
but are priced higher. These therapies have also been shown to have favorable 
cost-effectiveness profiles compared with older therapies; however, the cost-
effectiveness of INF-free regimens relative to each other is unclear. The objective 
of this study was to assess the cost-effectiveness of treating genotype 1 (GT1) HCV 
patients with AbbVie 3D (paritaprevir [developed by AbbVie and Enanta] /ritonavir/
